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Summary
Background. Pancreatic cancer is amongst the most chemoresistant malignancies. Expression of the cyclooxygenase-2
(COX-2) enzyme plays a major role in tumor progression and resistance to therapy. A Phase II study was undertaken to
determine the effect of gemcitabine by fixed-dose rate infusion (FDR), cisplatin and the COX-2 inhibitor, celecoxib, on
the 6-month survival rate in patients with metastatic pancreatic cancer.
Methods. The eligibility criteria included a pathologically or cytologically confirmed diagnosis of adenocarcinoma of
the pancreas. No prior gemcitabine therapy was allowed. Patients received a combination of gemcitabine 1000 mg/m2
over 100 minutes, cisplatin 35 mg/m2 I.V. on days 1 and 8, and celecoxib continuously at a daily dose of 800 mg. Cycles
were repeated every 21 days.
Results. Twenty-two patients with metastatic pancreas cancer were enrolled (median age, 59.5 years; M:F, 13:9 ). The
median number of cycles was 2 per patient. The median survival time was 5.8 months (90% CI, 3.6–7.6 months). The
probability of survival at 6 months was 46% (90% CI, 27–62%). The major toxicity was neutropenia with grade 3 or 4
toxicities seen in 65% of patients.
Conclusions. The addition of celecoxib to gemcitabine (by FDR) and cisplatin did not appear to increase activity of
the chemotherapy doublet in patients with advanced pancreatic cancer. Celecoxib alone may not be sufficient to sensitize
pancreatic cancer to the effects of conventional cytotoxic therapy.
Introduction
Pancreatic cancer is the fourth leading cause of cancer
death in the United States [1]. Despite an increase in the
number of systemic treatments available for pancreatic
cancer, the impact of therapy on the clinical course of this
disease has been modest [2]. The chemoresistant nature
of pancreatic cancer cells have limited the development of
effective therapies. Therefore, improvements in the out-
come of patients with pancreatic cancer are very much
dependent on the development of more effective systemic
agents with novel mechanisms of action.
The cyclooxygenase (COX) isoenzymes catalyze the
rate-limiting step in the conversion of arachidonic acid
into prostaglandins [3]. Recent evidence suggests that
COX-2 has a central role in pancreatic carcinogenesis and
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in the chemoresistance of established disease [4]. Work
from our institution and others showed that the COX-
2 isoenzyme is overexpressed in 45–75% of pancreatic
cancer [5, 6] and has been associated with increased inva-
siveness [7] and promotion of angiogenesis [8] Preclinical
evidence suggested that the COX-2 mRNA is stabilized by
mutations in the k-ras oncogene that are very frequently
present in pancreas cancer [9, 10]. Selective and non-
selective COX-2 inhibitors have been shown to induce
apoptosis [11] in pancreatic cancer cell lines as well as
potentiate the growth inhibitory effects of chemothera-
peutic agents including gemcitabine [6, 12]. Celecoxib, a
selective COX-2 inhibitor, inhibited the growth of human
pancreatic cancer cell lines [13]. Clinical trials suggested
an improved safety profile of celecoxib in comparison
to non-selective COX inhibitors with respect to gastroin-
testinal and renal toxicity [14, 15].
Gemcitabine is the most commonly used cytotoxic
agent in advanced pancreatic cancer [2]. However,
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objective response rates of patients with pancreatic cancer
treated with this drug are less than 10% without clinically
significant impact on survival (6 month and median sur-
vival of 46% and 5 to 6 months, respectively) [16]. Gemc-
itabine is therefore combined with other cytotoxic drugs to
improve its efficacy in this disease. Phase II trials of gem-
citabine and cisplatin in advanced pancreatic cancer have
demonstrated objective response rates of 11 and 31%,
6 month and median survival of 64% and 7 to 8 months,
respectively [17, 18]. Subsequently, two Phase III studies
comparing the gemcitabine and cisplatin combination to
gemcitabine were conducted [19, 20]. The median time
to progression and the overall response rate were signifi-
cantly higher in the combination arms. However, the sur-
vival duration, though longer with the combination ther-
apy, did not achieve statistical significance. These trials
utilized the conventional short infusion (30–45 minutes)
schedules of gemcitabine. A second approach to improve
the efficacy of gemcitabine was based on improving its
cellular activation to deoxycytidine triphosphate. The cel-
lular uptake and activation of gemcitabine was saturable
and hence infusion dose rate dependent. An optimized
fixed dose infusion schedule of gemcitabine was shown to
increase the intracellular accumulation of deoxycytidine
triphosphate [21]. A randomized phase II trial compar-
ing the fixed dose rate (FDR) infusion schedule of gem-
citabine to bolus administration yielded a higher objec-
tive response rate and 1-year survival with the FDR [22].
Therefore, the FDR schedule of gemcitabine in combi-
nation with cisplatin could provide an active cytotoxic
regimen that would be further enhanced by incorporating
a targeted agent such as celecoxib.
We hypothesized that COX-2 inhibition by celecoxib
would significantly improve the outcome of patients with
metastatic pancreatic cancer treated with combination
chemotherapy. To test this hypothesis we treated patients
with metastatic pancreatic cancer with the triple drug
combination of gemcitabine by fixed dose infusion, cis-
platin, and celecoxib. The primary endpoint of the study
was survival at 6 months.
Materials and methods
Patient eligibility
Patients with a histologic or cytologic diagnosis of pan-
creatic adenocarcinoma and metastatic disease were el-
igible. Patients were required to have a Southwest On-
cology Group (SWOG) performance status of 0–2, a life
expectancy of at least 3 months, and adequate hemato-
logic, renal and hepatic function defined by the follow-
ing parameters: neutrophil count ≥1,500/mm3, platelet
count≥100,000/mm3, creatinine≤1.5 mg/dL, total serum
bilirubin ≤3.0 mg/dl and aspartate transaminase (AST)
less than 3 times upper limit of the institutional normal
range (ULN). Patients were excluded if they had neu-
roendocrine cancer or other active malignancy within
the preceding year except for adequately treated basal
cell, squamous cell skin cancer, or in-situ cervical can-
cer. Additional exclusion criteria included active peptic
ulcer disease within the preceding year, and previous
chemotherapy for pancreatic cancer except for patients re-
lapsing more than 6 months after completion of adjuvant
chemotherapy. All patients provided a signed informed
consent in accordance with the Institutional Human In-
vestigation Committee guidelines prior to enrolment on
the study.
Study design and treatment plan
Gemcitabine (Gemzar, Eli Lilly, Indianapolis, IN) at a
dose of 1,000 mg/m2 was administered intravenously
on days 1 and 8 of each treatment cycle at a rate of
10 mg/m2/minute. Cisplatin 35 mg/m2 was given intra-
venously on days 1 and 8 following gemcitabine infusion
and with adequate hydration. Celecoxib (Celebrex, Pfizer
Crop., New York, NY) was administered orally at a dose
of 400 mg twice daily. In order to achieve steady state
levels prior to initiation of chemotherapy, celecoxib was
started on day −7. Celecoxib was continued until the end
of study participation. Treatment cycles were repeated
every 21 days.
Dose reductions were made on day 8 based on the toxi-
city encountered within that cycle. Doses of gemcitabine,
celecoxib and cisplatin were held for a neutrophil count
less than 500/mm3 or platelets less than 50,000/mm3 on
the day of treatment. The gemcitabine and cisplatin doses
were reduced by 20% for any grade 3 hematologic tox-
icity. All three drugs were held for grade 3 or 4 non-
hematologic toxicity until recovery to grade 1 or lower.
Dose adjustments on day 1 of a cycle were based on the
worst grade of toxicity in the preceding cycle as follows:
patients who sustained either febrile neutropenia or grade
4 myelosuppression received gemcitabine and cisplatin
at 60% of the commencing dose of the previous cycle.
For grade 3 and 4 non-hematologic toxicities excluding
alopecia, nephrotoxicity, nausea, or vomiting the doses of
gemcitabine and cisplatin were reduced by 20%. Treat-
ment for patients with renal toxicity was guided by the
serum creatinine on the day of cisplatin administration
and the extent of renal toxicity in the prior cycle. Patients
with a serum creatinine of 1.6–2.0 times X ULN had a
dose reduction of cisplatin by 40%. Patients with a serum
creatinine ≥ 2.1× ULN had the cisplatin dose held. Cis-
platin dose was also adjusted based on the peak creatinine
level during the previous cycle. For a creatinine of 2.1–
3.0× ULN, the cisplatin dose was reduced by 25% if the
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serum creatinine level at the next dose was ≤1.5× ULN.
Patients with a peak serum creatinine level of 3.1–4.5×
ULN had the subsequent dose of cisplatin reduced by
50% if the serum creatinine level on the day of the next
treatment was ≤1.5× ULN. When the serum creatinine
level was >4.5× ULN, no further cisplatin was given.
Celecoxib was withheld for patients who developed pep-
tic ulcer disease or a rise in serum creatinine level. The
celecoxib dose was not adjusted for other toxicities. Once
the dose of any drug was reduced during a treatment cycle,
re-escalation was not permitted in subsequent cycles.
A new cycle of therapy could only begin if the
neutrophil count was ≥1,500/mm3, platelet count was
≥100,000/ mm3 and all relevant non-hematological toxi-
cities were grade 1 or lower. Patients requiring a delay in
therapy of longer than 2 weeks because of ongoing tox-
icities or more than two dose reductions were removed
from the study. In addition, patients were removed from
the study for any of the following reasons: disease pro-
gression, unacceptable toxicity, or withdrawal of consent.
On-study evaluation
Standard efficacy endpoints of objective response, time
to progression, and survival were assessed. Imaging stud-
ies were performed at baseline and repeated after every
2 cycles of therapy or whenever there was any clinical
suspicion of disease progression. Tumor responses were
determined by the RECIST criteria and categorized as
complete response, partial response, disease progression,
or stable disease. Objective responses required at least one
additional confirmatory follow up scan at least 3 weeks af-
ter the documentation of response. CA 19-9 was measured
at baseline and after each cycle of treatment. Response by
CA19-9 was defined as a decrease in CA 19-9 of at least
20% after the first cycle of treatment. Survival was mea-
sured from study registration to date of death or last follow
up. Time to progression (TTP) was measured from study
registration to the date of first documented progressive
disease, or death. Time to treatment failure (TTF) was
measured from study registration to the date of first doc-
umented progressive disease, or date off treatment due to
toxicity, patient refusal, or death, whichever occurred first.
Toxicities were evaluated at a minimum on days 1 and 8 of
each cycle and graded according to National Cancer Insti-
tute Common Toxicity Criteria (NCI-CTC) version 2.0.
Statistical methods
This phase II trial was planned with a Simon two-stage
optimal design [23]. Survival for at least 6 months after
the date of registration was considered a treatment suc-
cess. We wished to distinguish these regions of the true,
unknown success rate: at least 0.60 versus at most 0.80.
The 2-stage design called for a maximum of 28 evaluable
patients, 17 in Stage 1 and 11 in Stage 2. Patients were
considered evaluable for the primary endpoint (6-month
survival, yes/no) if they had completed at least two cy-
cles of therapy. The design had a type I error of 0.142
and power of 0.901. We needed at least 11 successes (i.e.,
6-month survivors) among the first 17 evaluable patients
to justify beginning Stage 2 of the study. After accruing
22 patients (over 16 months), there were 17 evaluable pa-
tients. With only 9 confirmed 6-month survivors in Stage 1
of the trial, we concluded that the sample success propor-
tion (9/17 = 53%) better supported the null hypothesis
that the true, unknown success rate was at most 0.60.
Exact, minimum-width 90% confidence intervals (CI)
for response and toxicity rates were calculated using the
Casella method [24] as implemented in StatXact software
[25]. Standard Kaplan-Meier estimates of the censored re-
sponse duration and censored survivorship functions were
computed. Due to the small sample sizes, survival statis-
tics (e.g., median) were estimated more conservatively
using linear interpolation [26] among successive event
times on the Kaplan-Meier curves.
Results
Patient characteristics
Patient characteristics are outlined in Table 1.Twenty-two
patients were enrolled onto the study between January
2002 and May 2003. Data was collected until February 25,
2004. The median age at study entry was 59.5 years
(range 41–77 years). There were proportionally more
males (59%). Eighty-two percent of the patients had
a performance status of 1. Twenty patients had liver
Table 1. Characteristics of the 22 patients with advanced pancreatic
cancer treated with gemcitabine, cisplatin and celecoxib
Characteristics Number Percentage Years
















metastases and two patients had only peritoneal metas-
tases. No patient received prior chemotherapy or radiation
treatment.
Treatment administration
A total of 91 cycles were administered with a median of
2 cycles per patient (range 0 to 11). Seventeen patients
received two or more cycles of therapy and were evalu-
able for the primary endpoint. Two patients received no
therapy for the following reasons: one patient was lost
to follow up after registration, and one did not meet the
eligibility criteria. Three patients received only day 1 of
cycle 1 for the following reasons: myocardial infarction,
bacterial peritonitis, and rapid disease progression. Fif-
teen of seventeen patients required dose reductions. The
most common causes for dose reduction were neutrope-
nia (9 patients), thrombocytopenia (3 patients), and renal
toxicity (3 patients).
Survival
Survival and response were analyzed on an intention to
treat basis. The Kaplan- Meier estimate of survival for the
Figure 1. The Kaplan-Meier estimate of overall survival in the 22 patients with metastatic pancreatic cancer enrolled on the study. The dashed lines
represent the 90% confidence interval (CI) about each successive estimate of the survival rate. The median survival was 5.8 months (90% CI, 3.6–7.6
months). The 6-month survival rate was 45% (90% CI, 27–62%).
22 patients is given in Figure 1. The median survival time
was 5.8 months (90% CI, 3.6–7.6 months). The 6-month
survival rate was 46% (90% CI, 27–62%). Two patients
are still alive (at 9.9 and 12.3 months) for a censoring rate
of 9.1%.
Objective response, TTF, TTP
Three patients had a partial response (PR) and 7 patients
had stable disease (SD). The PR and SD rates were 14%
(90% CI, 0.05–0.31) and 32% (90% CI, 0.18–0.50), re-
spectively. Two of the three responders have progressed
after 5 and 6 months from the time of documented re-
sponse. One patient was still free of progression at 7.3
months. The baseline CA19-9 was available on 18 of the
22 patients. After the first cycle, CA 19-9 was available
on 11 patients. A 20% decrease in CA 19-9 was observed
in 5 of the 11 patients accounting for a response rate by
CA19-9 of 45.5%.
The median time to treatment failure was 1.3 months
(90% CI, 1.1–3.7 months). The median time to progres-
sion was 1.8 months (90% CI, 0.4–3.1 months). The
Kaplan-Meier estimate of the time to progression curve
is given in Figure 2.
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Figure 2. The Kaplan-Meier estimate of time to progression in the 22 patients with metastatic pancreatic cancer who were treated with gemcitabine,
cisplatin and celecoxib. The dashed lines represent the 90% confidence interval (CI) about each successive estimate of the progression-free rate. The
median time to progression was 1.8 months (90% CI, 0.4–3.1 months).
Toxicity
Two patients did not receive any treatment and could not
be evaluated for toxicity. The treatment was generally well
tolerated in the outpatient setting. No treatment-related
deaths were reported. Table 2 summarizes the grade 3
and 4 toxicities observed on the study. Seven episodes of
grade 4 toxicities were observed in 6 patients. The most
common grade 3–4 toxicities were hematologic. Thirteen
patients had grade 3–4 neutropenia. Infections were ob-
served in four patients. One patient had a grade 3 febrile
neutropenia, and three patients had non-neutropenic in-
fections (1 grade 3 bacterial peritonitis and 2 grade 2 in-
fections). Nine patients had grade 3 thrombocytopenia.
Three of these patients developed bleeding on the study
(1 grade 3 GI bleeding source unspecified, 1 grade 3 up-
per GI bleeding due to esophageal varices, and 1 grade
2 vaginal bleeding). Nine patients required hospitaliza-
tion (3 cardiac events, 2 dehydration and anemia, and one
each for neutropenic fever, bacterial peritonitis with GI
bleeding, biliary stent replacement, and diarrhea).
Grade 2 asthenia was observed in 7 patients. Three
patients had grade 2 renal toxicity requiring dose reduc-
tions of cisplatin. Three patients developed cardiac events
while on treatment. The first patient who was known to
have a history of atrial tachyarrhythmia developed atrial
flutter during the second cycle of therapy. The second
patient who was known to have stable coronary artery
disease developed unstable angina during the first cycle
Table 2. The frequency of grade 3-4 treatment related toxicities in
20 patients with pancreatic cancer expressed as the worst toxicity per
patient. Toxicity was assessed using the NCI-CTC version 2.0 scale for
toxicity grading
Grade 3 Grade 4
Type of toxicity Number Percentage Number Percentage
Neutropenia 10 50 3 15
Leukopenia 3 15 1 5
Thrombocytopenia 9 45 0 0
Anemia 6 30 1 5
Infection 2 30 0 0
Angina 1 5 1 5
Arrhythmia 1 5 0 0
Bleeding 1 5 1 5
Dehydration 2 10 0 0
Diarrhea 2 10 0 0
Nausea 4 20 0 0
Vomiting 3 15 0 0
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of therapy. This patient was hospitalized and underwent
a cardiac catheterization, which revealed extensive coro-
nary artery disease. The patient was managed medically
and received 10 additional cycles of therapy with no fur-
ther cardiac events. The third patient who was not known
to have any previous cardiac disease developed a my-
ocardial infarction after receiving day 1 of cycle 1. The
patient subsequently had a cardiac catheterization, which
revealed extensive coronary artery disease and was re-
moved from the study.
Discussion
The COX-2 enzyme is a modulator of carcinogenesis,
apoptosis, and angiogenesis in pancreatic cancer. In pre-
clinical models of human pancreatic cancer, inhibition
of the COX-2 enzyme potentiated the activity of gemc-
itabine [6, 11, 13]. Based on this evidence, we hypothe-
sized that combining celecoxib with cytotoxic chemother-
apy would result in an improvement in survival of
patients with metastatic pancreatic cancer. The rationale
for the cytotoxic regimen was based on the results of two
phase III trials demonstrating a higher response rate and
longer time to progression with gemcitabine and cisplatin
as compared to single agent gemcitabine [19, 20] in those
trials a trend towards improvements in survival was noted
that was statistically insignificant. To further improve the
activity of gemcitabine, a fixed dose rate infusion schedule
that has been shown to increase the intracellular activa-
tion of gemcitabine was used. The regimen used in this
study was therefore a modification of previous dose and
schedules of gemcitabine and cisplatin combinations. The
modifications were based on the dose intensity of cisplatin
that was feasible in previous studies. The rationale for the
dose of celecoxib used in this study was the demonstrated
activity of celecoxib at 800 mg/day to inhibit intratumoral
activity of the COX-2 enzyme in non-small cell lung can-
cer [27], and the published benefit of this dose level in
the prevention of colorectal polyp formation in familial
adenomatous polyposis [28].
In the present study, the triple combination therapy of
gemcitabine, cisplatin, and celecoxib resulted in a 1-year
survival rate of 13% and a median survival of 5.8 months
in patients with metastatic pancreatic cancer. These results
are comparable to the previously reported survival rates
observed with single agent gemcitabine [16] administered
by a 30–45 minute infusion schedule. Several possible in-
terpretations for the observed results could be entertained.
First, COX-2 inhibitors may arrest cells at the G1-S phase
[12] and therefore antagonize the effects of S phase spe-
cific agents such as gemcitabine. A pulsatile schedule of
administration of celecoxib prior to chemotherapy could
potentially decrease the cell cycle effects of celecoxib
while maintaining its pro-apoptotic effects. Such a sched-
ule may be evaluated initially in preclinical models of hu-
man pancreatic cancer. Second, recent data from preclin-
ical models suggest that nimesulide, a selective COX-2
inhibitor, can stimulate angiogenesis and growth of pan-
creatic cancer cell lines that do not express the COX-2 en-
zyme [29]. Conversely, the pro-apoptotic effects of cele-
coxib may be best demonstrated in cells overexpressing
COX-2. In this study, no evaluation of baseline tumoral
COX-2 expression was performed because of a lack of
a reliable assay. Future studies may address the benefits
of combining celecoxib with cytotoxic therapy only in
patients whose tumors overexpress the COX-2 enzyme.
Third, the increased hematologic toxicity with the cur-
rent regimen required dose reductions in the majority of
the patients on the trial. The impact of the dose reduction
might have attenuated any potential benefit from com-
bining celecoxib with the gemcitabine plus cisplatin reg-
imen. Alternatively, the inhibition of the COX-2 enzyme
alone maybe insufficient to reverse the chemoresistance
in pancreatic cancer. Given some of the redundancies of
the cell signalling pathways, combinations of COX-2 in-
hibitors and other targeted molecules may be necessary
to significantly sensitize pancreatic cancer cells. Ongoing
trials evaluating the effects of combining celecoxib with
gemcitabine [30] or gemcitabine and irinotecan [31] may
further define the role of celecoxib in the treatment of
pancreatic cancer.
Preclinical observations suggested that COX-2 inhi-
bition may delay the recovery phase of chemotherapy-
induced myelosuppression [32]. An increase in myelo-
toxicity was also observed when celecoxib was combined
with paclitaxel and carboplatin in patients with non-small
cell lung cancer [27]. In our study, the incidence of grade
3-4 neutropenia (65%) was slightly higher than that re-
ported by Ko et al. (57%) with gemcitabine by fixed-dose
rate infusion and cisplatin [33].
Cardiovascular morbidity remains a concern with long-
term use of selective COX-2 inhibitors. In this trial, three
patients experienced cardiac events while on treatment.
All those patients had established pre-treatment cardiac
disease. Blanke et al. reported a similar increase in throm-
botic episodes in patients with colorectal cancer receiv-
ing irinotecan, 5-fluorouracil, and celecoxib [34]. The
increase in thrombotic complications could be due to
the higher dose of celecoxib used or the hypercoagu-
lable state of patients with metastatic cancer receiving
chemotherapy.
In conclusion, the antitumor activity of gemcitabine
by FDR and cisplatin was not improved with concurrent
administration of the COX-2 inhibitor celecoxib. This
lack of benefit of a COX-2 inhibitor does not rule out
the significance of the COX-2 enzyme as a target for
drug development in pancreatic cancer. Attempts to select
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patients who may respond to such therapy and the com-
bination of COX-2 inhibitors with novel targeted agents
would be of continued research interest.
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